By reducing tumor-favorable microenvironment factors such as CD68+ macrophage infiltration and changes to the profile of cytokines released by macrophages in the TME, Ad-ANGPTL4 treatment considerably reduced the development of HCC.[178]. The gene discussed is ANGPTL4; the disease is neoplasm.